Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P30DA011041 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims at assessing the feasibility of implementing an interventional cohort of people who inject drugs in Haiphong, Viet Nam.
For this purpose, the investigators will conduct a RDS survey to i) assess the current situation of drug use behaviour, HIV and Hepatitis C Virus (HCV) infection in the study population and ii) recruit participants for the longitudinal phase. The latter will consist of enroling the most difficult to reach People Who Inject Drugs (PWID) (those not followed by health centers), including early injectors, Men who have Sex with Men (MSM) and female sex workers (FSW) and following them up for 6 months in order to estimate the follow-up rate and preliminary estimates of HIV and HCV incidence.
Objectives:
The primary objective of the DRIVE-IN project is to evaluate the feasibility of implementing an interventional cohort of PWID in Haiphong. Such a cohort (DRIVE) will be instrumental in demonstrating the efficacy of a community-involved intervention integrating prevention and care in order to reduce HIV and HCV transmission among PWID in Haiphong.
The main expected result of DRIVE-IN is to demonstrate that enrolment and follow-up of various hard-to-reach subgroups of PWID is feasible in the local context. These feasibility objectives will be evaluated using a set of relevant indicators.
Design:
The research will first include a respondent-driven sampling (RDS) survey, including a maximum of 600 PWID. Then 250 RDS participants (i.e about a quarter of the future DRIVE cohort) will be selected for a longitudinal study, with an enrolment and 3 follow-up visits at week 4, 12 and 24. In parallel, four qualitative studies will be implemented: one study to explore how to reach the hardest-to-reach and most-at-risk PWID, one feed-back study on PWID feeling about their participation in the research, one study investigating the reasons of drop-outs, and a final study on the research process itself.
Endpoints:
The RDS will describe the target population and the patterns of drug use. The feasibility of implementing an interventional cohort will be evaluated on several indicators:
Study population RDS survey Inclusion criteria Age > 18 years Self-reported drug injector confirmed by a positive urinary test and either skin marks of injection or knowledge of injecting procedures Signed informed consent Non-inclusion criteria Unable of understanding informed consent and answering questionnaires
Longitudinal study Inclusion criteria Having participated to the RDS survey Signed informed consent specific to the longitudinal study Non-inclusion criteria Ongoing Methadone Maintenance Therapy (MMT) Ongoing antiretroviral therapy Health status not compatible with study follow-up Have a plan to move out of Haiphong over the next two years. Have been sentenced recently to a prison term
Follow-up and study visits contents:
Participants of the longitudinal phase will be followed at week 4, 12 and 24 (final visit). During the RDS, face-to-face questionnaires will be applied on drug use, sexual health, and referral to care and repeated at each follow-up visit, along with the record of medical events. In addition, a urinary test will be collected at the RDS to assess the range of recent drugs used, and repeated at the final follow-up visit (week 24). Finally, at the RDS and final visit, HIV, HCV, Hepatitis B Virus (HBV) serology will be done along with appropriate counselling.
Sample size:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| no intervention is assessed | Other |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Cohort Participants Attending the Last Follow-up Visit at W52 | Number of participants who were followed up and not lost to follow-up after enrolment into cohort. | 52 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| HCV Seroconversion | Number of new HCV infection among HCV negative (at RDS) cohort participants over 1 year period | 52 weeks |
| HIV Seroconversion | Number of new HIV infection among HIV negative (at RDS) cohort participants over 1 year period. |
Not provided
Inclusion criteria
Exclusion criteria
Not provided
Not provided
Not provided
People who inject drugs living in Haiphong, Vietnam. The longitudinal phase will be restricted to those not followed by health care services, i.e. not taking methadone nor antiretroviral therapy
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicolas Nagot, MD,PhD | INSERM U1058 & University of Montpellier, France | Principal Investigator |
| Oanh Khuat Thi, MD, MSc | Supporting Community Development Initiatives (SCDI) | Principal Investigator |
| Don DesJarlais, PhD | Mount Sinai Beth Israel | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hai Phong Medical University | Haiphong | Vietnam |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26080690 | Background | Elliott JC, Hasin DS, Stohl M, Des Jarlais DC. HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users. AIDS Behav. 2016 Mar;20(3):548-54. doi: 10.1007/s10461-015-1113-z. | |
| 26075647 | Background | Perlman DC, Des Jarlais DC, Feelemyer J. Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? J Addict Dis. 2015;34(2-3):198-205. doi: 10.1080/10550887.2015.1059111. |
Not provided
Not provided
Not provided
People Who Injected Drugs (PWID), age > 18 years, with history of injecting drug use confirmed by a positive urine test and visual inspection of injection marks
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | People Who Injected Drugs (PWID) Respondent Driven Sample (RDS | 603 participants recruited through Respondent Driven Sample survey |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RDS |
| |||||||||||||
| Longitudinal Cohort |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | PWID RDS | 603 participants |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Cohort Participants Attending the Last Follow-up Visit at W52 | Number of participants who were followed up and not lost to follow-up after enrolment into cohort. | Participants were invited to follow-up visits at W4, W12, W24 and W52 | Posted | Count of Participants | Participants | 52 weeks |
|
|
52 weeks
Adverse events reported for cohort participants (n=250)
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | PWID Cohort | 250 participants | 9 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Overdose | General disorders | Non-systematic Assessment |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| NAGOT NICOLAS | UMR 1058 (Inserm/University of Montpellier/EFS) | +33 4 34 35 91 09 | n-nagot@chu-montpellier.fr |
Not provided
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| 52 weeks |
| Incidence of HCV Infection | The HCV incidence was calculated by 100person/year | 52 weeks |
| HIV Incidence | HIV incidence was calculated by 100person/year. With zero conversion, we choose 2.5% unilateral confidence interval. | 52 weeks |
| 26050614 | Background | Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, Des Jarlais DC. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy. 2015 Nov;26(11):1056-63. doi: 10.1016/j.drugpo.2015.04.015. Epub 2015 Apr 27. |
| 26032121 | Background | Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, Panopoulos A, Malliori M, Psichogiou M, Pharris A, Wiessing L, van de Laar M, Donoghoe M, Heckathorn DD, Friedman SR, Des Jarlais DC. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015 Sep;110(9):1453-67. doi: 10.1111/add.12999. Epub 2015 Jul 14. |
| 25540950 | Background | Des Jarlais DC. AIDS, people who use drugs, and altruism: reflection on a personal image. Subst Use Misuse. 2015 Mar;50(4):532-3. doi: 10.3109/10826084.2015.978185. Epub 2014 Dec 26. No abstract available. |
| 28800503 | Result | Michel L, Des Jarlais DC, Duong Thi H, Khuat Thi Hai O, Pham Minh K, Peries M, Vallo R, Nham Thi Tuyet T, Hoang Thi G, Le Sao M, Feelemyer J, Vu Hai V, Moles JP, Laureillard D, Nagot N; DRIVE Study Team. Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions. Drug Alcohol Depend. 2017 Oct 1;179:198-204. doi: 10.1016/j.drugalcdep.2017.07.004. Epub 2017 Aug 2. |
| 27178119 | Result | Des Jarlais D, Duong HT, Pham Minh K, Khuat OH, Nham TT, Arasteh K, Feelemyer J, Heckathorn DD, Peries M, Moles JP, Laureillard D, Nagot N; (The Drive Study Team). Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions. AIDS Care. 2016 Oct;28(10):1312-5. doi: 10.1080/09540121.2016.1178698. Epub 2016 May 13. |
| 27006257 | Result | Des Jarlais DC, Thi Huong D, Thi Hai Oanh K, Khue Pham M, Thi Giang H, Thi Tuyet Thanh N, Arasteh K, Feelemyer J, Hammett T, Peries M, Michel L, Vu Hai V, Roustide MJ, Moles JP, Laureillard D, Nagot N; DRIVE Study Team. Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam. Int J Drug Policy. 2016 Jun;32:50-6. doi: 10.1016/j.drugpo.2016.02.021. Epub 2016 Feb 27. |
| 28612212 | Result | Duong HT, Jarlais DD, Khuat OHT, Arasteh K, Feelemyer J, Khue PM, Giang HT, Laureillard D, Hai VV, Vallo R, Michel L, Moles JP, Nagot N; Drive Study Group. Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014. AIDS Behav. 2018 Jul;22(7):2161-2171. doi: 10.1007/s10461-017-1814-6. |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Medical Insurance | Count of Participants | Participants |
|
| Duration of Injection use | Median | Inter-Quartile Range | years |
|
| Number of drug injection (typical day) | Mean | Standard Deviation | injection per day |
|
| Injecting drug: heroin alone | Count of Participants | Participants |
|
| Injection with syringe already used by someone else (last 3 months) | Count of Participants | Participants |
|
| HIV positive | Count of Participants | Participants |
|
| Currently under Methadone Maintenance Therapy | Count of Participants | Participants |
|
| HCV positive | Count of Participants | Participants |
|
|
| Secondary | HCV Seroconversion | Number of new HCV infection among HCV negative (at RDS) cohort participants over 1 year period | HCV negative cohort participants with HCV test result available at W24 and/or W52. | Posted | Count of Participants | Participants | 52 weeks |
|
|
|
| Secondary | HIV Seroconversion | Number of new HIV infection among HIV negative (at RDS) cohort participants over 1 year period. | HIV negative cohort participants with HIV test result available at W24 and/or W52. | Posted | Count of Participants | Participants | 52 weeks |
|
|
|
| Secondary | Incidence of HCV Infection | The HCV incidence was calculated by 100person/year | HCV negative cohort participants with HCV test result available at W24 a/or W52 | Posted | Number | 95% Confidence Interval | infections per 100 person-years | 52 weeks |
|
|
|
| Secondary | HIV Incidence | HIV incidence was calculated by 100person/year. With zero conversion, we choose 2.5% unilateral confidence interval. | HIV negative cohort participants with HCV test result available at W24 a/or W52 | Posted | Number | 2.5% Confidence Interval | infections per 100 person-years | 52 weeks |
|
|
|
| 250 |
| 9 |
| 250 |
| 0 |
| 250 |
| AIDS | Immune system disorders | Non-systematic Assessment |
|
| Suicide | Psychiatric disorders | Non-systematic Assessment |
|
Not provided
Not provided